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Background and aims: We recently identiﬁed lysosomal acid lipase (LAL) deﬁciency, a recessive disease
caused by mutations in LIPA, in 3 patients with a clinical diagnosis of familial hypercholesterolemia (FH).
We aimed to determine the prevalence of LIPAmutations among individuals with a clinical FH diagnosis.
Methods: In 276 patients with phenotypic FH, in whom no genetic basis for their phenotype was found,
LIPA was sequenced. All variants were assessed for pathogenicity using a literature search and in silico
prediction models.
Results: We included 213 adults and 63 children with mean (±SD) LDL-C levels of 7.8 ± 1.3 and
4.4 ± 1.5 mmol/L, respectively. Twenty-one variants were identiﬁed. Six patients were heterozygous
carrier of a (potentially) pathogenic mutation. No homozygous LIPA mutation carriers were identiﬁed.
Conclusions: Our data show that LAL deﬁciency was not missed as diagnosis in our study population but
the frequency of heterozygous LIPA mutations implies that the FH population might be relatively
enriched with LIPA mutation carriers.
© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Lysosomal acid lipase (LAL) deﬁciency is a rare recessive lyso-
somal storage disease caused by mutations in LIPA (OMIM
#613497). LAL hydrolyses cholesteryl esters and triglycerides in
lysosomes and, as a consequence, dysfunction of this enzyme leads
to accumulation of cholesteryl esters and triglycerides in, among
others, hepatocytes, intestines and adrenal glands [1]. Depending
on the residual LAL activity, LAL deﬁciency can result in the very
severe and lethalWolman disease or the late onset cholesteryl ester
storage disease (CESD) [1]. CESD is typically characterized by hep-
atosplenomegaly and type IIb hyperlipidemia [2]. Recently, we
identiﬁed 3 siblings with a clinical diagnosis of familial hypercho-
lesterolemia (FH; type IIa hyperlipidemia) that were homozygous
for a mutation in LIPA [3,4]. At physical examination hep-
atosplenomegaly was not observed. It has been suggested thater, Department of Vascular
msterdam, The Netherlands.
rved.CESD should be considered as a differential diagnoses in patients
with clinical FH inwhom no FH mutation is identiﬁed [5]. Based on
the potential overlap, CESD might be underdiagnosed [4,6]. The
current standard of care for dyslipidemia in patients with CESD is
treatment with 3-hydroxy-3-methyl-glutaryl-CoA-reductase in-
hibitors (statins) [6]. However, reduction of plasma LDL-C levels in
these patients might potentially lead to increased intra-cellular
levels of cholesteryl esters, which may worsen the effects on liver
function [6]. Recently, Burton and co-workers showed that enzyme
replacement therapy (ERT; sebelipase alpha; Kanuma®) normalized
alanine aminotransferase levels and decreased hepatic fat content
in CESD patients, compared with placebo [7]. Since December 2015,
sebelipase alfa has been approved by the US Food and Drug
Administration (FDA) for treatment of patients with LAL deﬁciency.
It has been suggested that screening for LIPA mutations in pheno-
typically diagnosed FH patients without mutations in LDLR, APOB,
and PCSK9, might identify CESD patients who might be eligible for ERT
by sebelipase alfa. Therefore, we aimed to establish the prevalence
of LIPA mutations in patients with clinically, but not genetically
deﬁned FH.
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The study cohort comprised patients with a clinical FH pheno-
type in whom, after genetic analysis by Sanger sequencing, no
mutations had been identiﬁed in LDLR (OMIM #606945) or APOB
(OMIM #107730). LDLR was also analysed by MLPA (Multiplex
ligation-dependent probe ampliﬁcation) to detect major gene
rearrangements. The genetic studies were performed by the na-
tional referral laboratory for DNA diagnostics of inherited dyslipi-
demias at the Academic Medical Center of the University of
Amsterdam, the Netherlands. Given the low prevalence of muta-
tions in LDLRAP (#605747), leading to Autosomal Recessive Hy-
percholesterolemia, and PCSK9 (OMIM #607786), causing an FH-
like phenotype termed Autosomal Dominant Hypercholesterole-
mia, sequencing of these genes was only performed when homo-
zygous FH was suspected (for LDLRAP) or when patients fulﬁlled
the criteria for FH as published by Civeira and co-workers [8]. In-
dividuals with a secondary form of dyslipidemia or an LDL-C level
below the 95th percentile for age and gender were excluded. Ge-
netic analysis of LIPA was performed by direct Sanger sequencing
using Big Dye Terminators (ABI Prism V1.1) and products were run
on a Genetic Analyzer 3730 (Applied Biosystems, Foster City,CA).
Sequence data was analysed by the Sequencer package (GeneCodes
Co, Ann Arbor, MI). All identiﬁed variants were assessed forTable 1
Clinical characteristics of included patients.
Children (n ¼ 63) Adults (n ¼ 213)
Age, years ± SD 10.6 ± 3.7 53.3 ± 11.4
Male, n (%) 28 (44.4%) 77 (36.2%)
TC 6.4 ± 1.6 10.1 ± 1.6a
LDL-C 4.4 ± 1.5 7.8 ± 1.3
HDL-C 1.6 ± 0.4 1.4 ± 0.4b
TG 1.0 ± 0.6 2.2 ± 1.1b
TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol;
LDL-C, low density lipoprotein cholesterol. Lipid levels are in mmol/L.
a Data available for 211 patients.
b Data available for 202 patients.
Table 2
Genetic variants in LIPA identiﬁed in phenotypically diagnosed FH patients.
Region Variant SNP Wild type (n) Heterozygo
50-UTR c.215G > T rs570237654 179 2
50-UTR c.200 A > C rs1332326 88 77
50-UTR c.195 T > C e 180 1
50-UTR c.189G > A rs1332327 113 59
50-UTR c.91 A > C e 180 1
50-UTR c.71C > A rs553435176 179 2
50-UTR c.53C > T e 180 1
Exon 2 c.36G > A e 138 36
Exon 2 c.46 A > C rs1051338 157 101
Exon 2 c.67G > A rs1051339 224 43
Intron 2 c.1126C > T rs141302830 265 2
Exon 4 c.342C > T (p.Asp114Asp) rs371133960 265 1
Intron 4 c.42996delGT rs72468815 263 1
Intron 5 c.5395C > T rs2297472 166 75
Intron 6 c.67642G > A rs1556478 273 3
Exon 7 c.683 T > C (p.Phe228Ser) rs2228159 264 2
Exon 8 c.894G > A (p.Gln298Gln) rs116928232 269 2
Exon 9 c.913 T > A (p.Phe305Ile) e 268 1
Intron 9 c.966 þ 3 A > T rs201242614 268 1
Intron 9 c.966 þ 46C > T rs3802656 192 70
Intron 9 c.96731C > T rs114416580 181 1
MAF, minor allele frequency in our study population; NA, not available; NC, not covered
a Pathogenicity of variants was applied to the following in silico prediction models: S
frequencies as reported in the Genome of the Netherlands (GoNL) database and the Exopathogenicity using a literature search in PubMed and in silico
prediction models including SIFT/PROVEAN, PolyPhen2 and Muta-
tionTaster. The LIPA transcript NM_000235.3 was used throughout
all databases and in silico prediction models.
From all study subjects written informed consent was obtained,
allowing genetic analysis to determine the cause of inherited
dyslipidemias.
2. Results
We selected 276 patients (213 adults and 63 children) with a
phenotypic diagnosis of FH of whom 105 (38.0%) were male. The
mean age (±SD) of included patients was 53.3 ± 11.4 and 10.6 ± 3.7,
for adults and children, respectively (Table 1). Mean LDL-C levels
were 7.8 ± 1.3 mmol/L and 4.4 ± 1.5 mmol/L, respectively. A total of
21 variants were identiﬁed of which 16 were previously described
(see rs number in Table 2). Six patients were found to be hetero-
zygous carriers of a potentially pathogenic mutation. Two patients
were carriers of c.683 T > C in exon 7, encoding a phenylalanine to
serine amino acid substitution (p.Phe228Ser) that was predicted to
be pathogenic by all in silico prediction models used. Two patients
were carriers of the c.894G > A mutation in exon 8 (p.Gln298Gln)
which is a common synonymous but pathogenic variant among LAL
deﬁciency patients, affecting the splice site at the end of exon 8
(ClinVar RCV000185528.3) [9]. One patient was carrier of
c.913 T > A in exon 9, causing a phenylalanine to isoleucine sub-
stitution (p.Phe305Ile) that was predicted to be potentially patho-
genic by PolyPhen2, and one patient was carrier of c.966 þ 3 A > T,
affecting a splice site, to a similar extent as is predicted for the
known functional p.Gln298Gln variant in exon 8. Homozygous or
compound heterozygous carriers of (potentially) pathogenic LIPA
mutations were not identiﬁed.
3. Discussion
In this study we aimed to determine the prevalence of homo-
zygosity for LIPA mutations among individuals who were clinically
diagnosed with FH, but not genetically conﬁrmed. We identiﬁed 5us (n) Homozygous (n) (In silico) prediction
for pathogenicity and
literature dataa
MAF ExAC/GoNL
e Inconclusive 0.006 NC/0.001
16 Non-pathogenic 0.301 NC/0.492
e Inconclusive 0.003 NC/<0.0001
9 Non-pathogenic 0.213 NC/0.277
e Inconclusive 0.003 NA/<0.0001
e Inconclusive 0.006 NC/0.004
e Non-pathogenic 0.003 NC//<0.0001
7 Non-pathogenic 0.138 NA/<0.0001
12 Non-pathogenic 0.231 0.306/0.282
3 Non-pathogenic 0.091 0.104/0.086
e Inconclusive 0.004 0.0003//<0.0001
e Inconclusive 0.002 <0.0001/0.001
e Non-pathogenic 0.002 NC/0.016
10 Non-pathogenic 0.189 0.199/0.176
e Non-pathogenic 0.005 0.316/0.287
e Possibly pathogenic 0.004 <0.0001/<0.0001
e Pathogenic 0.004 0.001/0.001
e Possibly pathogenic 0.002 NA/<0.0001
e Pathogenic 0.002 <0.0001/<0.0001
7 Non-pathogenic 0.156 0.238/0.263
e Inconclusive 0.003 0.0001/<0.0001
.
IFT/PROVEAN, Polyphen-2, and Mutation Taster. ExAC/GoNL indicates minor allele
me Aggregation Consortium (ExAC) database for non-Finnish European individuals.
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heterozygous carriers of (potentially) pathogenic mutations were
identiﬁed, which shows that LAL deﬁciency was not missed as
diagnosis in our study population.
Recently, Pullinger and co-workers investigated the frequency of
a common LIPA mutation in 1357 patients with various types of
dyslipidemia. In this study, six individuals were found to be het-
erozygous carriers of c.894G> A of whom two had isolated elevated
LDL-C levels. After sequencing the heterozygous individuals for
other LIPA mutations, one patient with combined dyslipidaemia
(elevated LDL-C, elevated triglycerides, and low high density lipo-
protein cholesterol levels) was found to be a compound heterozy-
gous LIPAmutation carrier. In line with our results, no homozygous
LIPA mutation carriers were identiﬁed among individuals with
isolated elevated LDL-C levels [10].
The overall prevalence of LAL deﬁciency has been estimated to
vary between 1 in 40,000 to 1 in 300,000 individuals [6]. While
applying the Hardy Weinberg Equilibrium, one would expect to
identify at least one heterozygous LIPA mutation carrier in
100e274 individuals. The fact that we identiﬁed 5 heterozygous
carriers in 276 individuals with heterozygous FH might imply that
the FH population is relatively enriched with LIPA mutation car-
riers and we might have missed LAL deﬁciency patients due to the
relatively small study population. This would be in line with
the previous identiﬁcation of a family with three LAL deﬁciency
patients with a clear FH phenotype [4] and underlines the
importance of genetic testing for rare diseases in case clinical
phenotypes may overlap the phenotype of more prevalent disor-
ders. While considering the diagnosis of LAL deﬁciency it is,
however, of great importance to notice that LAL deﬁciency is an
autosomal recessive disease while FH due to mutations in LDLR,
APOB or PCSK9 is autosomal dominant. Moreover, it has been
shown that heterozygous LIPAmutation carriers (eg. the parents of
a patient with LAL deﬁciency) generally do not demonstrate a
hypercholesterolemic phenotype [3]. Therefore, it seems reason-
able to make a distinction between the diseases based on a thor-
ough clinical assessment, including an extensive family history and
determination of the lipid proﬁles of the parents or children of an
index case, rather than performing genetic testing for LIPA muta-
tions in all patients with an FH phenotype without a mutation in
LDLR, APOB or PCSK9.
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